CTRI/2018/07/014753进行中（未招募）4 期
Phase IV, Multicentre, Observer-Blind, Randomized, Parallel-Group, Comparative Study of Feracrylum Gel and Cetrimide Cream on Minor Traumatic Wounds in Non-Hospitalized Patients
试验速览
- 阶段
- 4 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Pms
入排标准
入选标准
- •1. Patients of either sex in the age group between 18 to 60 years
- •2. Patients who have minor traumatic wounds such as cuts, abrasions, lacerations caused by road traffic accidents and other causes
- •3. Patients with fresh/untreated wound
- •4. Patients who provide a signed informed consent to abide by the study requirements
排除标准
- •1. Patients with life threatening injuries
- •2. Patients with any wound requiring hospitalization
- •3. Patients with bruises
- •4. Patients with wounds deeper than subcutaneous tissue
- •5. Patients with wounds caused by animal bites and burns
- •6. Patients with pulse > 100/min, Systolic BP < 90mm Hg or Respiratory Rate beyond 10-29/min
- •7. Patients with altered sensorium (Glasgow coma scale of < 15)
- •8. Patients with severe bleeding or suspected internal hemorrhage
- •9. Patients with fractures
- •10. Patients with suspected internal injury to head, chest, abdomen, pelvis, spine or long bones
- •11. Patients with history of HIV, cardiac, hepatic, gastrointestinal, renal, pulmonary and skin diseases
- •12. Women who are lactating or with known pregnancy at the time of screening
- •13. Known hypersensitivity to any of the ingredients of the test / comparator formulation
- •14. Simultaneous participation in another clinical study
研究者
相似试验
进行中（未招募）
不适用
Phase IV, Double-blind, Multi-center, Randomized, Cross-over Study to Compare 0.10 mmol/kg of MultiHance R with 0.10 mmol/kg of Omniscan R in Magnetic Resonance Imaging MRI of the Brain - Crossover Comparison of MultiHance R and Omniscan R in Brain Tumorspatients sent to the sites with a request for assessment/diagnoses of certain/suspected brain neoplasmsMedDRA version: 6.1Level: PTClassification code 10029816EUCTR2006-001680-33-ITBRACCO IMAGING114
进行中（未招募）
不适用
Randomized, Multicenter, Double-Blinded, Phase IV Study Evaluating the Efficacy (as measured by Sustained Virological Response) and Safety of 360 µg Induction Dosing of Pegasys in Combination with Higher Copegus Doses in Treatment-naïve Patients with Chronic Hepatitis C Genotype 1 Virus Infection of High Viral Titer and Baseline Body Weight Greater than or Equal to 85 kggenotype 1 chronic hepatitis C infection of high viral titer and baseline body weight greater than or equal to 85 kgMedDRA version: 8.1Level: LLTClassification code 10008912Term: Chronic hepatitis CEUCTR2005-005507-41-HUF. Hoffmann-La Roche Ltd1,140
进行中（未招募）
不适用
Randomized, Multicenter, Double-Blinded, Phase IV Study Evaluating the Efficacy (as measured by Sustained Virological Response) and Safety of 360 µg Induction Dosing of Pegasys in Combination with Higher Copegus Doses in Treatment-naïve Patients with Chronic Hepatitis C Genotype 1 Virus Infection of High Viral Titer and Baseline Body Weight Greater than or Equal to 85 kg - PROGRESSgenotype 1 chronic hepatitis C infection of high viral titer and baseline body weight greater than or equal to 85 kgMedDRA version: 8.1Level: LLTClassification code 10008912Term: Chronic hepatitis CEUCTR2005-005507-41-NLF. Hoffmann-La Roche Ltd1,140
进行中（未招募）
1 期
Randomized, Multicenter, Double-Blinded, Phase IV Study Evaluating the Efficacy (as measured by Sustained Virological Response) and Safety of 360 µg Induction Dosing of Pegasys in Combination with Higher Copegus Doses in Treatment-naïve Patients with Chronic Hepatitis C Genotype 1 Virus Infection of High Viral Titer and Baseline Body Weight Greater than or Equal to 85 kg - PROGRESSEUCTR2005-005507-41-GBF. Hoffmann-La Roche Ltd1,140
进行中（未招募）
1 期
Randomized, Multicenter, Double-Blinded, Phase IV Study Evaluating the Efficacy (as measured by Sustained Virological Response) and Safety of 360 µg Induction Dosing of Pegasys in Combination with Higher Copegus Doses in Treatment-naïve Patients with Chronic Hepatitis C Genotype 1 Virus Infection of High Viral Titer and Baseline Body Weight Greater than or Equal to 85 kg - PROGRESSgenotype 1 chronic hepatitis C infectionMedDRA version: 8.1Level: LLTClassification code 10008912Term: Chronic hepatitis CEUCTR2005-005507-41-FRF. Hoffmann-La Roche Ltd1,140